Caption Management’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$39.7M Buy
632,200
+316,500
+100% +$25.3M 0.23% 91
2025
Q4
$30.1M Buy
315,700
+181,100
+135% +$17.8M 0.21% 110
2025
Q3
$13.1M Buy
134,600
+88,600
+193% +$9.18M 0.1% 209
2025
Q2
$4.94M Buy
46,000
+500
+1% +$50.6K 0.05% 410
2025
Q1
$4.59M Buy
+45,500
New +$4.58M 0.04% 419
2024
Q3
Sell
-234,000
Closed -$18M 1291
2024
Q2
$18M Buy
+234,000
New +$17.1M 0.28% 77
2023
Q4
Sell
-100,000
Closed -$5.28M 1359
2023
Q3
$5.28M Buy
+100,000
New +$5.24M 0.08% 306
2022
Q2
Sell
-60,000
Closed -$2.66M 1477
2022
Q1
$2.66M Buy
+60,000
New +$2.6M 0.03% 655
2018
Q4
Sell
-70,000
Closed -$2.69M 475
2018
Q3
$2.69M Buy
+70,000
New +$2.44M 0.15% 187

Other funds holding BSX

Caption Management's BSX Position: Q1 2026 in Review

Caption Management increased its Boston Scientific (BSX) stake by 311% in Q1 2026, buying an estimated $22.7M and bringing the position to 374,400 shares worth $23.5M. The position accounts for 0.14% of the portfolio, ranked #150.

Caption Management first reported a position in BSX in Q4 2018 and has held it in 10 quarters since. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Caption Management held 374,400 shares of Boston Scientific worth $23.5M as of Q1 2026.
  • Caption Management bought 283,400 Boston Scientific shares in Q1 2026, an estimated $22.7M.
  • Boston Scientific made up 0.14% of Caption Management's portfolio in Q1 2026, its #150 holding.
  • Caption Management first reported a position in Boston Scientific in Q4 2018 and has held it in 10 quarters since.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.